# Byterna Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/byterna-therapeutics

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.byterna.com
- Latest round: Angel (Dec 15, 2025)
- Investors on record: 3

## About

Based in Shanghai, China and founded in 2023, Byterna Therapeutics Ltd., trading as Byterna Therapeutics, specializes in biotechnology, particularly in mRNA-based therapies. In July 2026, Byterna Therapeutics raised a pre-series A funding from Efung Capital, InSilico Medicine and other investors.

Byterna Therapeutics offers a range of mRNA-based therapies designed to improve cancer treatment outcomes. The company is currently advancing its clinical research in the IIT pipeline for BR101, a circular mRNA (cmRNA)-based CAR-T therapy, targeting healthcare providers and research institutions focused on oncology.

The company's revenue generation is primarily structured through a subscription model for access to its mRNA therapies and related services. 

The company will use the latest funding to accelerate the clinical application of the world's first dual-target circular mRNA in vivo CAR-T pipeline; promote the development of an AI-based personalized circular mRNA tumor vaccine pipeline; and co-build a next-generation mRNA AI-Native R&D Engine with InSilico Medicine to enable intelligent capabilities across the entire chain from circular mRNA molecule design to clinical translation.

## Funding rounds

- Angel, Dec 15, 2025 — Efung Capital
- Angel, Nov 17, 2025 — FOF Capital, Beijing Sun-Novo Pharmaceutical Research Co.,Ltd.

## Investors

- FOF Capital (https://capitalatlas.ai/funds/fof-capital) — Angel
- Beijing Sun-Novo Pharmaceutical Research Co.,Ltd. — Angel
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Angel